Other Species / Isoforms
  A6 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
S2-p
______MsHQTGIQA
0 3
A6 (human) ______MsHQTGIQA S2-p
A6 iso3 (human) ______MSHQTGIQA S2
A6 (mouse) ______MsHQTGIQA S2-p
A6 (rat) ______MSHQTGIQA S2
Y81-p
DSQNAQGyEWIFIAW
0 1
A6 (human) DSQNAQGyEWIFIAW Y81-p
A6 iso3 (human) DSQNAQGYEWIFIAW Y81
A6 (mouse) DSQNAQGYEWIFIAW Y81
A6 (rat) DSQNAQGYEWIFIAW Y81
K118-ub
EFGGGHIkDEVFGTV
0 1
A6 (human) EFGGGHIkDEVFGTV K118-ub
A6 iso3 (human) EFGGGHIKDEVFGTV K118
A6 (mouse) EFGGGHIKDEVFGTV K118
A6 (rat) EFGGGHIKDEVFGTV K118
K135-ac
DVSLHGYkkYLLSQs
0 3
A6 (human) DVSLHGYkkYLLSQs K135-ac
A6 iso3 (human) DVSLHGYKKYLLSQS K135
A6 (mouse) DVSLHGYKKYLLsQs K135
A6 (rat) DVSLHGYRKYLLSQS R135
K136-ac
VSLHGYkkYLLSQss
0 1
A6 (human) VSLHGYkkYLLSQss K136-ac
A6 iso3 (human) VSLHGYKKYLLSQSS K136
A6 (mouse) VSLHGYKKYLLsQss K136
A6 (rat) VSLHGYRKYLLSQSs K136
K136-ub
VSLHGYkkYLLSQss
0 1
A6 (human) VSLHGYkkYLLSQss K136-ub
A6 iso3 (human) VSLHGYKKYLLSQSS K136
A6 (mouse) VSLHGYKKYLLsQss K136
A6 (rat) VSLHGYRKYLLSQSs K136
S140
GYkkYLLSQssPAPL
0 1
A6 (human) GYkkYLLSQssPAPL S140
A6 iso3 (human) GYKKYLLSQSSPAPL S140
A6 (mouse) GYKKYLLsQssPAPL S140-p
A6 (rat) GYRKYLLSQSsPAPL S140
S142-p
kkYLLSQssPAPLtA
Upstream
0 1
Treatment
  • ischemia
A6 (human) kkYLLSQssPAPLtA S142-p
A6 iso3 (human) KKYLLSQSSPAPLTA S142
A6 (mouse) KKYLLsQssPAPLTA S142-p
A6 (rat) RKYLLSQSsPAPLTA S142
S143-p
kYLLSQssPAPLtAA
Upstream
0 25
Treatment
  • nocodazole
A6 (human) kYLLSQssPAPLtAA S143-p
A6 iso3 (human) KYLLSQSSPAPLTAA S143
A6 (mouse) KYLLsQssPAPLTAA S143-p
A6 (rat) KYLLSQSsPAPLTAA S143-p
T148-p
QssPAPLtAAEEELR
0 1
A6 (human) QssPAPLtAAEEELR T148-p
A6 iso3 (human) QSSPAPLTAAEEELR T148
A6 (mouse) QssPAPLTAAEEELR T148
A6 (rat) QSsPAPLTAAEEELR T148
K158-ub
EEELRQIkINEVQTD
0 1
A6 (human) EEELRQIkINEVQTD K158-ub
A6 iso3 (human) EEELRQIKINESPED K158
A6 (mouse) EEELRQIKINEVQTD K158
A6 (rat) EEELRQIKISEVQTD K158
K171-ub
TDVGVDTkHQtLQGV
0 1
A6 (human) TDVGVDTkHQtLQGV K171-ub
A6 iso3 (human) TDVGVDTKHQTLQGV K178
A6 (mouse) TDVSVDTKHQTLQGV K171
A6 (rat) TDVSVDTKHQTLQGV K171
T174-p
GVDTkHQtLQGVAFP
0 2
A6 (human) GVDTkHQtLQGVAFP T174-p
A6 iso3 (human) GVDTKHQTLQGVAFP T181
A6 (mouse) SVDTKHQTLQGVAFP T174
A6 (rat) SVDTKHQTLQGVAFP T174
K192
EAFQALEKLNNRQLN
0 1
A6 (human) EAFQALEKLNNRQLN K192
A6 iso3 (human) EAFQALEKLNNRQLN K199
A6 (mouse) DAFQALEKLSKKQLN K192
A6 (rat) DAFQALEkLSKRQLN K192-ac
K192
EAFQALEKLNNRQLN
0 1
A6 (human) EAFQALEKLNNRQLN K192
A6 iso3 (human) EAFQALEKLNNRQLN K199
A6 (mouse) DAFQALEkLSKKQLN K192-ub
A6 (rat) DAFQALEKLSKRQLN K192
S277
MLYSSCKSRLLEIVE
0 1
A6 (human) MLYSSCKSRLLEIVE S277
A6 iso3 (human) MLYSSCKSRLLEIVE S284
A6 (mouse) MLYSSCKSPLLEIVE S277
A6 (rat) MLYSSCKsPLLDIVE S277-p
Y309-p
ELTADFLyEEVHPKQ
Upstream
0 146
Treatment
  • anti-CD3
  • Su11274
A6 (human) ELTADFLyEEVHPKQ Y309-p
A6 iso3 (human) ELTADFLYEEVHPKQ Y316
A6 (mouse) ELTADFLyDEVHPKQ Y309-p
A6 (rat) ELTADFLyDEVHPKQ Y309-p
S322-p
KQHAHKQsFAkPkGP
0 1
A6 (human) KQHAHKQsFAkPkGP S322-p
A6 iso3 (human) KQHAHKQSFAKPKGP S329
A6 (mouse) KQHAHKQSFAKPKGP S322
A6 (rat) KQHAHKQSFAKPKGP S322
K325-ac
AHKQsFAkPkGPAGK
0 2
A6 (human) AHKQsFAkPkGPAGK K325-ac
A6 iso3 (human) AHKQSFAKPKGPAGK K332
A6 (mouse) AHKQSFAKPKGPAGK K325
A6 (rat) AHKQSFAKPKGPAGK K325
K327-ac
KQsFAkPkGPAGKRG
0 2
A6 (human) KQsFAkPkGPAGKRG K327-ac
A6 iso3 (human) KQSFAKPKGPAGKRG K334
A6 (mouse) KQSFAKPKGPAGKRG K327
A6 (rat) KQSFAKPKGPAGKRG K327
R340-m1
RGIRRLIrGPAETEA
0 3
A6 (human) RGIRRLIrGPAETEA R340-m1
A6 iso3 (human) RGIRRLIRGPAETEA R347
A6 (mouse) RGIRRLIRGPAEAEA R340
A6 (rat) RGIRRLIRGPAEAEA R340
T349-p
PAETEATtD______
0 31
A6 (human) PAETEATtD______ T349-p
A6 iso3 (human) PAETEATTD______ T356
A6 (mouse) PAEAEATtD______ T349-p
A6 (rat) PAEAEATtD______ T349-p